The predictive value and the correlation of peripheral absolute monocyte count, tumor-associated macrophage and microvessel density in patients with colon cancer

Zhigui Li, MD, Zhaofen Xu, BM, Yuqian Huang, MD, Rui Zhao, MD, Yaping Cui, MD, Yong Zhou, MD, Xiaoting Wu, MD, FACS

Abstract
The tumor microenvironment plays a pivotal role in cancer progression. The purpose of the present study was designed to evaluate the predictive value of peripheral absolute monocyte count, tumor-associated macrophage, microvessel density, and to clarify the correlation between them in patients with colon cancer.

A series of 216 patients with colon cancer were enrolled in this study. The peripheral absolute monocyte count was obtained from preoperative routine blood test. Tumor-associated macrophage and microvessel density were assessed on tissue microarray by immunohistochemistry.

The one, three, five-year overall survival rate for the low absolute monocyte count group was 98.4%, 91.1%, 87.1%, respectively; and for the high absolute monocyte count group was 94.6%, 83.7%, 77.2%, respectively (P = .046). The one, three, five-year progression-free survival rate for the low absolute monocyte count group was 94.4%, 87.1%, 85.5%, respectively; and for the high absolute monocyte count group was 90.2%, 75.0%, 73.9%, respectively (P = .024). Univariate and multivariate analysis showed that there was a strong association between peripheral monocyte count and clinical outcome. The correlation between peripheral absolute monocyte count, tumor-associated macrophage, and microvessel density were not observed.

The peripheral absolute monocyte count was an independent prognostic factor for overall survival and progression-free survival in colon cancer. The high absolute monocyte count was significantly associated with poor outcome.

Abbreviations: AMC = absolute monocyte count, MVD = microvessel density, OS = overall survival, PFS = progression-free survival, TAMs = tumor-associated macrophages.

Keywords: colon cancer, colorectal cancer, microvessel density, monocyte, tumor-associated macrophage

1. Introduction
Colon cancer represented the major cause of cancer-related mortality worldwide,[1] with the growing incidences in many countries.[2] The 5-year and 10-year relative survival rates for patients with colon cancer were 65% and 58%, respectively.[3] Until now, the most important prognostic factor for colon cancer was clinical stage at the time of diagnosis.[1,4] However, this predictive factor was insufficient to predict the outcome accurately. At present, an active area of study focused on how to distinguish the subset of patients who were at high risk of recurrence and metastasis.

It was well known that systemic inflammation plays a pivotal role in the carcinogenesis and cancer progression. Because inflammatory response correlated with alterations of peripheral blood leukocytes, the correlation between peripheral monocyte count and cancer has garnered increased attention. The peripheral absolute monocyte count (AMC) has been demonstrated to correlate with the outcome in various malignancies.[5–7] Tumor-associated macrophages (TAMs) derived from the peripheral monocytes were divided into 2 subgroups: the M1 macrophages responsible for inflammation, antitumor and immune response; the M2 macrophages involving in angiogenesis.[8,10] Microvessel density (MVD) counting the endothelial vessels and measuring their density, was considered to be one of the representative and useful marker of angiogenesis. Several studies demonstrated that the MVD can predict prognosis in various malignancies, such as lung cancer,[5,11] colorectal cancer,[12] and breast cancer.[13,14] These studies presented the hypothesis that the peripheral monocyte count reflects the density of TAMs which was associated with MVD in the tumor microenvironment.[14–16] Nevertheless, these evidences were insufficient to draw the consistent conclusion. The role and the correlation between AMC, TAMs, and MVD have not yet been elucidated in colon cancer.

Therefore, the purpose of the present study was designed to evaluate the predictive value of AMC, TAMs, and MVD and to
clarify the correlation between them in patients with colon cancer.

2. Materials and methods

2.1. Patients

In our study, a total of 216 patients with colon cancer were recruited between February 2012 and March 2013 from the Department of Gastrointestinal Surgery, West China Hospital. The study was approved by the Ethics Committee of West China Hospital of Sichuan University. If patients had inflammatory bowel disease, or received preoperative therapy, or underwent emergency surgery for perforation/obstruction, they were excluded from this study. All patients were followed-up every 3 months in the first postoperative year, every 6 months in the subsequent year until October 2017 or death. The follow-up period was defined as the duration of time from the date of surgery to the date of the last known contact or the date of death. Progression-free survival (PFS) was calculated from the date of surgery to the date of recurrence or metastasis. Overall survival (OS) was calculated from the date of surgery to the date of death by any causes. The last follow-up date was the end of October 2017.

2.2. Blood sample analysis

Preoperative routine blood test and differential leukocyte count were obtained within 2 weeks before surgery. AMC was calculated by total leukocyte count multiply the percentage of monocytes. The low AMC group was defined as AMC < 0.35 \times 10^9/L based on the average value.

2.3. Tissue microarray and Immunohistochemistry

All tumor samples obtained from West China Hospital Biobank of Sichuan University were made into the donor paraffin blocks. Paraffin sections were initially evaluated by hematoxylin and eosin staining and the representative areas of tumor tissue were marked in the donor paraffin blocks. Using a specialized manual tissue arrayer, 1.5mm diameter cylinders were sampled from these marked regions and then placed into an empty paraffin block. CD68 has been used as a specific marker to identify TAMs. TAMs, and MVD, Kaplan–Meier method to analyze the OS and PFS. Covariates with a P value ≤.10 in the univariable analysis were included in the multivariable analysis. Multivariate Cox proportional hazards regression analysis was employed to evaluate the prognostic factors.

2.4. Morphometrical assay

An image analysis system (Olympus upright microscope-BX53, Japan) was utilized. In tumor sections, 3 nonoverlapping, most immunostained fields (hot spots) were selected at low magnification (×100). Individual TAMs were counted at ×400 magnification, MVD was counted at ×200 magnification. TAMs and MVD were evaluated by 2 independent pathologists.

2.5. Statistical analysis

All statistical analyses were performed using SPSS 19.0 software (SPSS, Inc., Chicago, IL), and 2-sided P value of < .05 was considered statistically significant. We used Spearman’s analysis to calculate the correlations of AMC, TAMs, and MVD, Kaplan–Meier method to analyze the OS and PFS. Covariates with a P value ≤.10 in the univariable analysis were included in the multivariable analysis. Multivariate Cox proportional hazards regression analysis was employed to evaluate the prognostic factors.

3. Results

In the present study, a total of 216 patients with stage I to III colon cancer were included. Details about patient’s information were shown in Table 1. Of these, there were 125 males and 91 females. The median age of the patients at the initial surgery was 64 years old (range: 22–89 years old). Around 127 patients had primary tumors located in the right colon, and 89 had primary tumors located in the left colon. There were 68 patients with poorly differentiated adenocarcinoma and 148 patients with middle or well differentiated adenocarcinoma (Fig. 1A–D). The distributions of clinical stages were as follows: stage I, 18 patients; stage II, 131 patients; stage III, 67 patients. The median follow-up from surgery was 60 (5–69) months. During the follow-up period, 37 out of 216 patients were dead at the last follow-up time. At diagnosis, the median AMC (quartile range) was 0.32 (0.22–0.44) × 10^9/L. In tumor tissue, the median (quartile range) of TAMs, MVD was 37.0 (24.5–55.5), 12.0 (7.0–19.0), respectively (Fig. 2A–D). No significant correlations between AMC and TAMs (r = 0.093, P = .171), AMC and
MVD \( (r = -0.024, \ P = .721) \), TAMs and MVD \( (r = -0.008, \ P = .912) \) were found (Fig. 3A–C).

When all patients were divided into 2 groups by AMC, the 1, 3, 5-year OS rate for the low AMC group was 98.4%, 91.1%, 87.1%, respectively; and for the high AMC group was 94.6%, 83.7%, 77.2%, respectively (log-rank test, \( P = .046 \)). During the follow-up period, 16 (12.9%) were dead in the low AMC group; 21 (22.8%) were dead in the high AMC group (Fig. 4A). The 1, 3, 5-year PFS rate for the low AMC group was 94.4%, 87.1%, 85.5%, respectively; and for the high AMC group was 90.2%, 75.0%, 73.9%, respectively (log-rank test, \( P = .024 \)). During the follow-up period, 18 (14.5%) had metastatic disease in the low AMC group; 24 (26.1%) had metastatic disease in the high AMC group (Fig. 4B).

The low TAMs group was defined as TAMs \(<40 \) based on the average value. When all patients were divided into 2 groups by TAMs, there were no differences in the OS rates (log-rank test, \( P = .341 \)) and the PFS rates (log-rank test, \( P = .111 \)) (Fig. 4C and D). Similarly, when the low MVD was defined as MVD \(<13 \) based on the average value, all patients were divided into 2 groups by MVD, there were no differences in the OS rates (\( P = .596 \)) and PFS rates (\( P = .581 \)) (Fig. 4E and F).

In the univariate analysis, lymph node involvement, clinical stage, differentiation grade, diabetes mellitus, AMC significantly correlated with the OS and PFS. Because of clinical stage-based on tumor invasion depth, lymph node involvement and metastasis, only clinical stage entered the multivariate analysis. The multivariate analysis showed that there was a significant association between clinical stage, differentiation grade, AMC, with OS (Table 2) and PFS (Table 3). The low AMC was significantly associated with better outcome.

4. Discussion

The present study has shown that the preoperative AMC was an independent prognostic factor in colon cancer; the high AMC was significantly associated with poor outcome. The result supported the hypothesis that monocyte plays an important role in cancer progression.

It was well known that monocytes can be divided into 2 main subsets: classical monocytes participating in inflammatory responses, nonclassical monocytes alleviating inflammatory properties and accelerating revascularization and wound healing.[17] Several receptor–ligand pairs, such as CCL2/CCR2, CCL5/CCR5, CXCL12/CXCR4, CX3CL1/CX3CR1, VEGFR1/VEGF-A, regulated the recruitment of monocytes into the tumor tissue.[18] After migrating into tumor tissue, monocytes differentiated into tumor-associated macrophages. Classical monocytes induced by IFN-\( \gamma \), LPS or TNF or GM-CSF generally differentiated into M1 macrophages playing an important role in proinflammation and tumor suppression. On the contrary, nonclassical monocytes induced by IL-4 and IL-13 differentiated into M2 macrophages playing immunosuppressive and tumor-promoting roles via TNF-alpha dependent MMP induction, production of interleukin (IL)-10,[19] the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PDL1) pathway.[20,21]
In previous studies, the peripheral monocyte count has been reported to be an useful prognostic factor in patients with various malignancies. Matsuo et al [24] reported that peripheral AMC was significantly associated with myometrial tumor invasion, pelvic lymph node metastasis, clinical stage; elevated AMC was significantly associated with poor outcome in patients with endometrial cancer. Kumagai et al [25] reported that peripheral AMC was significantly associated with poor outcome in lung adenocarcinoma, peripheral AMC significantly correlated with TAMs. Shibutani et al [14] reported that the peripheral AMC was an useful prognostic factor in colorectal cancer. Hu et al [7] reported that elevated peripheral AMC was significantly associated with poor outcome in colorectal cancer. Our study focused on colon cancer, furtherly testified the preoperative peripheral monocyte count was an independent prognosis in colon cancer.

The majority of previous studies showed that elevated TAMs was significantly associated with poor outcome in various malignancies, such as prostate cancer, lung cancer, hepatocellular carcinoma, and breast cancer. Based on the phenomenon that both peripheral monocyte count and TAMs were negatively associated with the outcome in various
Figure 4. Kaplan–Meier survival curves for OS and PFS according to AMC, TAMs and MVD. (A) The OS rate was significantly better in the low AMC group than in the high AMC group. (B) The PFS rate was significantly better in the low AMC group than in the high AMC group. (C) There was no significant difference in OS rates according to TAMs. (D) There was no significant difference in PFS rates according to TAMs. (E) There was no significant difference in OS rates according to MVD. (F) There was no significant difference in PFS rates according to MVD. AMC = absolute monocyte count, MVD = microvessel density, OS = overall survival, PFS = progression-free survival, TAMs = tumor-associated macrophages.
malignancies, it was postulated that the peripheral AMC was significantly associated with the density of TAMs in the tumor microenvironment. Until now, few studies have demonstrated that peripheral monocyte count significantly correlated with the density of TAMs. Nevertheless, there were ambivalent results in colorectal cancer. Some studies proved the direct correlation, our study was inconsistent with this theory. There were several explanations for this ambivalent phenomenon. First of all, the selective bias was not entirely eliminated. Second, there was no standardized method for quantification of TAMs and MVD levels. CD68 has been considered as a marker of the total tumor associated macrophages, but did not distinguish the M1 and M2 subtypes.

The M2 TAMs had the ability of producing various proangiogenic factor including angiogenic chemokines VEGF, TGF-β, and PDGF, thereby promoting angiogenesis and cancer progression. There was general agreement that abnormal vasculatures play an important role in malignant aggressiveness, including tumor growth and metastasis. New vessel formation significantly increased the oxygen and nutrient for tumor cells. The vessels in tumors were divided into 2 types: pre-existing normal vessels and newly formed tumor vessels. CD34 has been considered as a marker of the tumor angiogenesis. Counting the endothelial vessels and measuring their density, also called MVD, was considered the most representative and useful tool for evaluating angiogenesis. As a matter of fact, the majority of previous studies supported the hypothesis that MVD plays a crucial role in cancer progression and prognosis. Nevertheless, several studies showed the opposite finding that MVD had no significant correlation with outcome and pathological features. The relationships between MVD and pathological features in colon cancer were still controversial. However, neither the correlation between MVD and pathological features nor direct correlation between TAMs and MVD were observed in our study.

The exact mechanism of the relationship between TAMs and angiogenesis was complex. Even though the majority of previous studies proved the direct correlation, our study was inconsistent with this theory. There were several explanations for this ambivalent phenomenon. First of all, the “hot spot” approach was the most common method for evaluating MVD and TAMs in various malignancies, areas of interest were selected at a low power magnification (×100), and the density of TAMs and MVD was counted at high power field (×400 or ×200, respectively). The selective bias was not entirely eliminated. Second, there was no standardized method for quantification of TAMs and MVD levels. CD68 has been considered as a marker of the total tumor associated macrophages, but did not distinguish the M1 and M2 subtypes.

### Table 2

| Variable                  | Univariate | Multivariate (95%CI) | P   |
|---------------------------|------------|----------------------|-----|
| Gender                    | 0.297      |                      |     |
| Male                      |            |                      |     |
| Female                    |            |                      |     |
| Age (median, range)       | 0.027      | 1                    | .200|
| <60                       |            |                      |     |
| ≥60                       |            | 1.688 (0.758-3.761)  |     |
| Tumor invasion depth      | 0.249      |                      |     |
| T1+T2                     |            |                      |     |
| T3+T4                     |            |                      |     |
| Lymph node involvement    | 0.003      |                      |     |
| No                        |            |                      |     |
| Yes                       |            |                      |     |
| Stage                     | 0.003      | .033                 |     |
| I+II                      |            |                      |     |
| III                       |            | 2.094 (1.062-4.127)  |     |
| Differentiation           | 0.000      | .002                 |     |
| Poor                      |            |                      |     |
| Middle or well            |            |                      |     |
| Tumor site                | 0.207      |                      |     |
| Right colon               |            |                      |     |
| Left colon                |            |                      |     |
| Diabetes mellitus         | 0.022      | .133                 |     |
| No                        |            |                      |     |
| Yes                       |            |                      |     |
| Hypertension              | 0.070      | .713                 |     |
| No                        |            |                      |     |
| Yes                       |            |                      |     |
| AMC                       | 0.046      | .037                 |     |
| Low AMC                   |            |                      |     |
| High AMC                  |            |                      |     |
| TAMs                      | 0.341      |                      |     |
| Low                       |            |                      |     |
| High                      |            |                      |     |
| MVD                       | 0.596      |                      |     |
| Low                       |            |                      |     |
| High                      |            |                      |     |

**AMC** = absolute monocyte count, **OS** = overall survival, **TAMs** = tumor-associated macrophages.

### Table 3

| Variable                  | Univariate | Multivariate (95%CI) | P   |
|---------------------------|------------|----------------------|-----|
| Gender                    | 0.336      |                      |     |
| Male                      |            |                      |     |
| Female                    |            |                      |     |
| Age (median, range)       | 0.006      | 1                    | .057|
| <60                       |            |                      |     |
| ≥60                       |            | 2.128 (0.977-4.635)  |     |
| Tumor invasion depth      | 0.166      |                      |     |
| T1+T2                     |            |                      |     |
| T3+T4                     |            |                      |     |
| Lymph node involvement    | 0.001      |                      |     |
| No                        |            |                      |     |
| Yes                       |            |                      |     |
| Stage                     | 0.001      | .013                 |     |
| I+II                      |            |                      |     |
| III                       |            | 2.226 (1.181-4.197)  |     |
| Differentiation           | 0.000      | .001                 |     |
| Poor                      |            |                      |     |
| Middle or well            |            |                      |     |
| Tumor site                | 0.906      |                      |     |
| Right colon               |            |                      |     |
| Left colon                |            |                      |     |
| Diabetes mellitus         | 0.038      | .212                 |     |
| No                        |            |                      |     |
| Yes                       |            |                      |     |
| Hypertension              | 0.075      | .948                 |     |
| No                        |            |                      |     |
| Yes                       |            |                      |     |
| AMC                       | 0.024      | .019                 |     |
| Low AMC                   |            |                      |     |
| High AMC                  |            |                      |     |
| TAMs                      | 0.111      |                      |     |
| Low                       |            |                      |     |
| High                      |            |                      |     |
| MVD                       | 0.581      |                      |     |
| Low                       |            |                      |     |
| High                      |            |                      |     |

**AMC** = absolute monocyte count, **MVD** = microvessel density, **PFS** = progression-free survival, **TAMs** = tumor-associated macrophages.
TAMs. CD34 was expressed not only in endothelial cells of small vessels, but also in inflammatory cells, lymphatic cells.

In conclusion, our results demonstrated that preoperative AMC was an independent prognosis in colon cancer, and elevated AMC was significantly associated with poor outcome. Based on the present evidences, neither the correlation between AMC and TAMs nor the correlation between TAMs and MVD were observed. It was emphasized that this conclusion should be confirmed in further study before making a final decision.

Acknowledgments
All samples were collected from West China Hospital Biobank of Sichuan University. We thanked staffs (Department of West China Hospital Biobank) for offering assistance in the process of collecting samples. We also thanked staffs (Department of Pathology, The Second People’s Hospital of Neijiang City, Sichuan Province) for help during the experiment.

Author contributions
ZGL designed the study and wrote this manuscript. ZFX and ZGL conducted experiments. YQH and RZ collected the clinical data. RZ and YPC performed the statistical analysis. YZ and XTW reviewed the manuscript and proofread the final version. All the authors have read and approved the final manuscript.

Conceptualization: Rui Zhao.
Investigation: Zhaofen Xu, Yaping Cui.
Resources: Yuqian Huang.
Supervision: Yong Zhou, Xiaoting Wu.
Writing – original draft: Zhigui Li.

References
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.
[2] Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009;18:1648–94.
[3] Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016;66:271–89.
[4] Marech I, Ammendola M, Sacco R, et al. Tumour-associated macrophages correlate with microvascular bed extension in colorectal cancer patients. J Cell Mol Med 2016;20:1373–80.
[5] Shigekawa K, Kosaka T, Kitano S, et al. Tumor-associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci 2013;104:1112–9.
[6] Koh YW, Kang HJ, Park C, et al. The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin’s lymphoma: correlation with tumor-associated macrophages. Oncologist 2012;17:871–80.
[7] Shigekawa K, Urakawa N, Nakamura T, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci 2013;104:1112–9.
[8] Chen P, Huang Y, Bong R, et al. Tumor-associated macrophage promotes angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin Cancer Res 2011;17:7230–9.
[9] Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Brit J Cancer 2002;87:694–701.
[10] Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Brit J Cancer 2006;94:1825–32.
[11] Uzzan R, Nicolas P, Cucherat M, et al. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004;64:2941–55.
[12] Shiokawa K, Urakawa N, Nakamura T, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci 2013;104:1112–9.
[13] Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 2015;212:435–45.
[14] Hagemann T, Robinson SC, Schule M, et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteinases. Carcinogenesis 2004;25:1543–9.
[15] Giu T, Shimokado A, Sun Y, et al. Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflamm 2012;2012:693083.
[16] Shen SL, Fu SJ, Huang XQ, et al. Elevated preoperative peripheral blood monocyte count predicts poor prognosis for hepatocellular carcinoma after curative resection. BMC Cancer 2014;14:744.
[17] Shiokawa K, Urakawa N, Nakamura T, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci 2013;104:1112–9.
[18] Hagemann T, Robinson SC, Schule M, et al. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteinases. Carcinogenesis 2004;25:1543–9.
[19] Gosselin D, Link VM, Romanoski CE, et al. Environment drives selection and function of enhancing tumour-associated macrophage identities. Cell 2014;159:1327–40.
[20] Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 2015;212:435–45.
[21] Gui T, Shimokado A, Sun Y, et al. Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflamm 2012;2012:693083.